Berenberg: Novo Nordisk drop after investor day an overreaction

Berenberg says Novo Nordisk’s ~8% fall after the investor day is an overreaction, while investors remain nervous about 2027. Analysts cite expected price pressure and skepticism around the CagriSema launch; they say the story looks more interesting from 2028.